Menu Search
Equities

Nyxoah SA

NYXH:BRU

Nyxoah SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)7.80
  • Today's Change-0.10 / -1.27%
  • Shares traded3.17k
  • 1 Year change+68.10%
  • Beta0.5378
Data delayed at least 15 minutes, as of Nov 22 2024 09:46 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform5
Hold2
Sell0
Strong Sell0

Share price forecast in EUR

The 4 analysts offering 12 month price targets for Nyxoah SA have a median target of 14.50, with a high estimate of 17.80 and a low estimate of 10.00. The median estimate represents a 83.54% increase from the last price of 7.90.
High125.3%17.80
Med83.5%14.50
Low26.6%10.00

Earnings history & estimates in EUR

On Nov 06, 2024, Nyxoah SA reported 3rd quarter 2024 losses of -0.496 per share. This result was in line with the consensus of the 6 analysts following the company and under-performed last year's 3rd quarter results by 86.47%.
The next earnings announcement is expected on Mar 13, 2025.
Average growth rate-17.77%
Nyxoah SA reported annual 2023 losses of -1.55 per share on Mar 05, 2024.
Average growth rate-34.42%
More ▼

Revenue history & estimates in EUR

Nyxoah SA had 3rd quarter 2024 revenues of 1.27m. This missed the 1.38m consensus estimate of the 6 analysts following the company. This was 187.07% above the prior year's 3rd quarter results.
Average growth rate+20.29%
Nyxoah SA had revenues for the full year 2023 of 4.35m. This was 40.99% above the prior year's results.
Average growth rate+479.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.